scientists have revealed that they have identified an enzyme, which is involved in the regulation of immune system T cells, that can help in treating asthma and boosting the effects of certain cancer therapies.
The research by Johns Hopkins Kimmel Cancer Center found that mice without the enzyme SKG1 were resistant to dust mite-induced asthma, while mice with melanoma and missing the enzyme, developed far fewer lung tumors.
Jonathan D. Powell said that if they can develop a drug that blocks the enzyme in a way that mimics what happens when the enzyme is missing, we would not only have a treatment to inhibit asthma, but also a drug that could be used in conjunction with other experimental therapies aimed at helping the immune system fight cancer.
The study found that SKG1 enzyme promotes the production of T helper 2 cells, which become overactive in asthma and other allergies in a sort of runaway case of inflammation.
The study was published online in Nature Immunology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app